The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate–resistant HER2-overexpressing breast cancer
Jangsoon Lee(The University of Texas MD Anderson Cancer Center), Naoto T. Ueno(University of Hawaiʻi at Mānoa)
Cited by 2
Related Papers
Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt
|Cancer Research|2007|115
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
|Molecular Cancer Therapeutics|2007|81
PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase
|Clinical Cancer Research|2010|64
Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis
|Molecular Cancer Therapeutics|2020|33
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer
|Journal of Experimental & Clinical Cancer Research|2024|24